Ocuphire Pharma Hits New 52-Week High of $4.42, Up 154.71%

Ocuphire Pharma, Inc. has reached a significant milestone by hitting a new 52-week high of USD 4.42 on March 2, 2026. This achievement marks a remarkable increase of 154.71% over the past year, significantly outperforming the S&P 500, which has seen a gain of 17.36% during the same period. As a microcap company in the Pharmaceuticals & Biotechnology sector, Ocuphire Pharma has a market capitalization of USD 234 million. Despite its recent stock performance, the company remains in a loss-making position, with a negative return on equity of -577.66%. The stock's price-to-book ratio stands at 39.18, indicating a premium valuation relative to its book value. The company does not offer a dividend, and its debt-to-equity ratio is reported at -4.99, reflecting a unique financial structure. The previous 52-week low for Ocuphire Pharma was USD 0.65, highlighting the substantial growth the stock has experienced over the past year.